Caliper and Covaris Establish Co-Marketing Agreement to Simplify Next Generation Sequencing
HOPKINTON, Mass., Feb. 23, 2011 /PRNewswire/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP) and Covaris Inc., Woburn, Mass., today announced a co-marketing agreement which will leverage Covaris' acoustic DNA shearing platforms and Caliper's automation and microfluidics technologies to develop automated workflows for next generation sequencing experiments. Caliper has developed a complete suite of solutions for library construction, sample analysis, and nucleic acid fractionation, which significantly reduces manual manipulations, increases throughput and improves sample-to-sample consistency.
"Our Sciclone NGS, LabChip GX, and LabChip XT have become critical tools in leading next generation sequencing laboratories already utilizing Covaris' technology," said Kevin Hrusovsky, President and Chief Executive Officer of Caliper Life Sciences. "This collaboration is a logical next step toward simplifying workflows for scientists challenged with meeting the growing demands of next generation sequencing sample preparation. As sequencing technologies move from the lab bench to the clinic, it is critical that integrated solutions offer consistency and sample tracking."
"Covaris provides a wide variety of next-gen sample prep solutions for the evolving needs of sequencing laboratories relative to nucleic acid shearing and sample extraction," said Jim Laugharn, Covaris President and Chief Executive Officer. "Covaris recognizes the importance of high quality sample preparation as a fundamental component for advanced life science systems, such as in Next Generation DNA Sequencing."